alexa HIV/AIDS Vaccine Design and Strategies
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

HIV/AIDS Vaccine Design and Strategies

Rupali Saxena*, Gourav Mishra, Batul Diwan and Archana Tiwari

School of Biotechnology, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Airport Bypass Road, Bhopal, Madhya Pradesh, India

*Corresponding Author:
Rupali Saxena
School of Biotechnology
Rajiv Gandhi Proudyogiki Vishwavidyalaya
Bhopal, MP
E-mail: [email protected]

Received date: May 23, 2013; Accepted date: June 24, 2013; Published date: June 28, 2013

Citation: Saxena R, Mishra G, Diwan B, Tiwari A (2013) HIV/AIDS Vaccine Design and Strategies. J Vaccines Vaccin 4:190. doi: 10.4172/2157-7560.1000190

Copyright: © 2013 Saxena R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Acquired Immuno Deficiency Syndrome or AIDS was first recognized in the early 1980’s. Although, with the use of antiretroviral medication, the life expectancy of an HIV infected patient can be elongated temporarily, but there is neither a known cure nor a vaccine for AIDS. This paper reviews the approaches undertaken in developing a preventive mechanism against HIV. Animal models were selected for HIV-1 vaccine development and strategies were developed where isolates of HIV-1 were taken from patients and injected in chimpanzees, but these failed to prove as a hope. Subsequently epitope driven vaccines that target the global variability of HIV was introduced. To serve this purpose computer driven methods for increasing the efficiency of vaccines like Epi-Assembler and Vaccine CAD were developed. Inducing production of broadly reactive and neutralizing antibodies could also potentially counteract HIV-1 diversity. HIV-1 Virus like Particles (VLPs) consists of viral gag proteins that self-assemble into particular structures analogous in size and morphology to immature HIV-1 particles. As a non-infectious, replication - deficient particles, the VLPs are much safer compared to traditional vaccines.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version